Intravenous Lidocaine Infusion Reduce Postoperative Pulmonary Complications in Patients Undergoing Minimally Invasive Esophagectomy

Launched by SICHUAN CANCER HOSPITAL AND RESEARCH INSTITUTE · Nov 13, 2023

Keywords

ClinConnect Summary

This clinical trial is studying whether an infusion of intravenous lidocaine can help reduce problems in the lungs after a type of surgery called minimally invasive esophagectomy, which is often performed to treat esophageal conditions. The researchers want to find out if lidocaine can lower the chances of patients developing issues like pneumonia, atelectasis (when parts of the lung collapse), or pulmonary edema (fluid in the lungs) after their surgery. Participants will be randomly assigned to receive either the lidocaine infusion or a placebo (a substance with no active medication) during their hospital stay.

To be eligible for this trial, participants need to be between 18 and 85 years old and scheduled for the surgery. They should be generally healthy or have mild to moderate health issues, as determined by a specific medical classification. However, people with serious mental health disorders, liver or kidney problems, certain heart conditions, or allergies to local anesthetics cannot participate. If someone joins the study, they will receive careful monitoring and support throughout the process. It's important to note that the trial is not yet recruiting participants, but it aims to provide valuable insights into improving patient care after surgery.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients between 18 and 85 years of age with a recent schedule for MIE are screened for this study. Patients who show clear consciousness and ASA status I - III will be included as eligible participants.
• Exclusion Criteria:
• • The exclusion criteria are as follows: patients with severe psychiatric disorders, such as schizophrenia, depression, dementia, etc.; severe hepatic insufficiency (concentration of glutamic oxaloacetic transaminase, glutamic pyruvic transaminase or bilirubin ≥2.5 times the upper limit of normal); renal impairment (creatinine clearance \<60 mL/min); allergy to amide local anesthetics; history of seizures; presence of II/III atrioventricular block; patients with severe sinus bradycardia or sick sinus syndrome; patients with Adams-Stokes syndrome or pre-excitation syndrome; intracardiac block (e.g. complete bundle branch block, atrioventricular block); serum potassium ion concentration below 2.5 or above 5.0 mmol/L; PH\>7.55 or PH\<7.2. Patients will be discontinued if any of the following situations occur: the patient has an allergic reaction, severe cardiovascular events that cannot be managed with symptomatic treatment, and the patient is unwilling to continue the study.